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observational, and 14% employed hybrid methods, including chart review or survey. 
Only 20% used independent observers. Three quarters (76%) reported descriptive 
statistics. Of 9 multi-centre studies, one used a random effects regression model to 
account for “centre clustering”, and 8 reported pooled data (3 of which used a “mean 
of centre averages” approach). Eleven studies (52%) compared two groups, of which 3 
applied an analytical design aiming to defect statistical differences, and 2 reported 
a sample size calculation. ConClusions: This review of T&M studies revealed that 
descriptive designs are most common (analytical designs using power calculations 
seem rare). Multi-centre comparator studies rarely use random effects regression 
models to account for “centre clustering”, though considered the method of choice 
to produce valid confidence intervals around point estimates. In general, statistical 
methodology is scarcely reported, affecting overall study credibility.
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objeCtives: Subgroup analyses of randomized trial data are performed to provide 
estimates of average treatment effects for patients with specific characteristics. They 
inform adoption and re-imbursement decisions by identifying groups of patients 
with favourable risk-benefit or cost-effectiveness ratios. They may also inform deci-
sions regarding the conduct and design of future clinical studies. However, subgroup 
analyses are essentially observational (patients are not randomized between sub-
groups) and there is a risk that the differences observed between subgroups may 
be due to chance rather than reflecting true effects. This risk is exacerbated as 
typically the same data are used to both select relevant subgroups and to estimate 
subgroups effects leading to biased estimates and underestimation of uncertainty. 
This tendency increases as the number of subgroups tested increases. A number of 
measures are recommended to reduce the risk of bias including: pre-specification, 
consideration of biological plausibility, and correction of inference for multiple 
testing. However, the risk of bias is not obviated by pre-specification, correction 
for multiplicity may lead to discounting of true subgroup effects, and biological 
plausibility may not be a particularly specific test. In addition, common cognitive 
and process biases associated with decision-making such as the action impera-
tive, optimism bias, anchoring, and group think may further lead to the inherent 
uncertainty in subgroup analyses to be effectively underestimated.  MetHoDs AnD 
Results: We demonstrate three techniques that may help to counteract these 
biases: graphical inference methods clearly illustrate the inherent uncertainty in 
subgroup analysis; Bayesian shrinkage estimation can reduce the effect of anchoring 
on the observed subgroup effects and encourage consideration of regression to the 
mean; and reframing exercises (for example, considering the credibility of biological 
plausibility arguments as if they had been mooted a priori) may counter optimism 
bias. ConClusions: These techniques are illustrated using a published subgroup 
analysis from the PLATO trial (NCT00391872)
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objeCtives: Along with uncertainty around the parameters and the initial param-
eter value assumptions used in health-economic evaluation models, an analy-
sis of the uncertainty around the model inputs/outputs is essential. Parameter 
importance analysis (PIA) provides an explicit framework to quantitatively iden-
tify the contribution of each uncertain input to the output uncertainty. There are 
several methods available to be used in PIA. The objectives of this research were 
to investigate different PIA methods with the pros and cons of each method and 
identify the most robust method with respect to different initial parameter value 
assumptions. MetHoDs: A health economic model for heart failure is developed 
to serve as a basis to implement different PIA methods. Six alternative methods 
are applied: One-way sensitivity analysis, rank correlation analysis, analysis of 
covariance (ANCOVA), dominance analysis, standardized regression analysis and 
expected value of perfect parameter information (EVPPI) analysis. Initial parameter 
assumptions are varied and the robustness of each method is assessed with respect 
to how close the parameter importance rankings are with different initial param-
eter assumptions. Results: Each technique/initial parameter values’ assumption 
combination generates a different ranking for the importance of the parameters that 
explain the uncertainty around the expected net monetary benefit with £20,000/
QALY. EVPPI is the most robust method with respect to different initial parameter 
assumptions. However it is the most demanding method in terms of computation 
time. On the opposite side, one-way sensitivity analysis is the least computation 
time demanding method; however the importance rankings are very susceptible 
to change with different initial assumptions. Other Monte-Carlo simulation based 
methods (e.g. ANCOVA, dominance, standardized regression and rank correlation 
analysis) are alternative PIA methods, which generate rather robust rankings with 
different initial parameter assumptions. These alternative methods require sub-
stantially less computation times compared to EVPPI with high consistency and 
robustness to different initial value assumptions.
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objeCtives: Treatment switching is an important problem in Health Technology 
Assessment (HTA), particularly in oncology, which can often bias trial results. 
Although a variety of statistical approaches have been advocated for adjusting 
trials subject to treatment switching these all assume that Individual Patient Data 
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objeCtives: A set of disease states for patients with schizophrenia was previ-
ously published using a statistical clustering method, applied to Positive and 
Negative Syndrome Scale (PANSS) data from US patients. While factor analyses of 
the PANSS have shown remarkable stability of the structure across international 
populations, it is unknown whether similar multidimensional disease states would 
also be stable. Using data from the European Schizophrenia Cohort (EuroSC), a 
2-year observational study in 1,208 schizophrenia patients, we examined the fac-
tor structure of the PANSS and identified disease states using the same clustering 
method as previously. MetHoDs: A principal component analysis (PCA) was con-
ducted using the Kaiser criterion and varimax rotation on PANSS items, followed 
by a k-means cluster analysis on PANSS scores for items most strongly correlated 
with the PCA domains. For each cluster, a level (low, moderate, high) was assigned 
to each domain based on the cluster centres values. Kappa statistics were used 
to measure the agreement in assignment between the published and the derived 
states sets. Results: Five factors accounting for 56% of total variance were obtained 
from the PCA (positive symptoms, negative symptoms, cognitive impairment, mood 
disorder, and hostility). As in the analysis of patients in the initial US study, rates 
of change in root mean squared distance became small after six clusters. When 
assigning the two sets of states based on levels of positive, negative, and cognitive 
impairment, the simple, Cicchetti-Allison, and Fleiss-Cohen weighted Kappa sta-
tistics (95% CI) were, 0.418 (0.401-0.435), 0.568 (0.553-0.584), and 0.692 (0.676-0.709), 
respectively. ConClusions: The factor structure, number of discrete states, and 
combinations of levels of symptoms in states were similar in US and European 
populations. Resulting moderate-to-substantial agreement in assignment suggests 
that disease states obtained using k-means clustering from the PANSS generalise 
across international populations.
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objeCtives: The use of subsequent therapies has the potential to confound assess-
ment of overall survival (OS) in oncology trials, in particular for trials in early lines 
of therapy and for malignancies with several registered or investigational treatment 
options. Standard intent-to-treat analysis is biased, since treatment choices are 
likely to be influenced by events associated with mortality risk, such as disease pro-
gression. We review and compare available statistical methods to obtain unbiased 
estimates of OS effects in presence of subsequent therapies. MetHoDs: Marginal 
structural modeling methods include inverse-probability of censoring weighting 
(IPCW) and inverse-probability of treatment weighting (IPTW). These methods 
explicitly model both treatment choices and effects of treatments on mortality. 
Rank-preserving structural failure time models (RPSFT) instead depend on paramet-
ric assumptions regarding the effect of investigational and subsequent therapies 
on survival, and require non-standard estimation methods such as G-estimation 
or iterative parameter estimation (IPE). We compare the results with the different 
methods with data from the Lux Lung 1 trial of the tyrosine kinase inhibitor afatinib 
in non-small cell lung cancer. Results: IPCW and IPTW require detailed informa-
tion on covariates that influence treatment choices and are sensitive to model 
misspecification. RPSFT may not yield a single estimate of treatment effects due 
to limitations of the G-estimation procedure. All methods were consistent with a 
potential OS benefit from afatinib, but the hazard ratio varied from 0.583 (p= 0.038) 
with the pre-specified IPCW method to 0.894 (0.281) with RPSFT/IPE. ConClusions: 
The proposed methods for obtaining unbiased OS estimates in presence of sub-
sequent therapies rest on assumptions that cannot be tested empirically. There 
is currently no accepted standard method; pre-specification of model choice is of 
importance as well as testing alternative methods. Care should be taken to avoid 
unbalance in subsequent therapy and to record specific information on adminis-
tered treatments with potential OS effects.
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objeCtives: To review design characteristics of T&M studies applied to health care, 
with a focus on choice of study design, statistical methodology, and handling of 
multi-centre data. MetHoDs: A PubMed search was performed using key search 
terms including “time and motion” (MeSH Term) AND any of the following: cost 
(analysis), (health) economics, observation(al), and prospective. Articles (English; 
2008 or later) were selected based on the following criteria: (1) observational study 
using T&M methodology; and (2) task-based data collection. Studies that measured 
broad aggregate health care professional tasks/hospital workflows, in the absence of 
task- or event-specific timings, were excluded. Results: Of 191 identified abstracts, 
151 were excluded during screening; upon review, 21 of 40 remaining were retained 
for detailed assessment. Half (48%) were applicable to Europe, of which 2 were 
multi-country studies. Medical interventions studied were: drug (48%), diagnostic 
process (14%), medical procedure (24%), and IT systems to improve clinical manage-
ment (e.g. EMR) (14%). The majority (86%) of studies were hospital-based, 86% were 
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objeCtives: Whether new medical technology is implemented may depend 
on the balance between costs and effects, but also on practical constraints. 
Examples are a fixed health care budget and a maximum clinically acceptable 
risk of adverse events. However, the impact of compliance with such constraints 
cannot be handled explicitly in the current value of information (VOI) framework. 
Our objective was to demonstrate proper handling of constraints by extending 
the VOI framework through separation of cost, effect, and constraint compo-
nents. MetHoDs: The proposed VOI extension was investigated in a simulation 
study comparing two hypothetical drugs and their side effects. The VOI exten-
sion was also applied to a clinical study concerning the cost-effectiveness of 
carotid intima-media thickness measurements to improve treatment guidance 
of patients at high risk of cardiovascular disease. Results of the standard VOI 
analysis, considering only costs and effects, were compared with results from the 
extended VOI analysis explicitly considering constraints. Results: Standard VOI 
results may under- or overestimate the value of additional research compared 
to extended VOI results. In our clinical example, with penalties of $2 and $5 
per dollar budget exceedance, standard values for the Expected Value of Perfect 
Information (EVPI) of $24, and $1,490 were found, with corresponding values of 
$239, and $565 for the extended EVPI. Ignoring the budget constraint in the stand-
ard EVPI analysis therefore resulted in a underestimation of $214 ($2 penalty) and 
an overestimation of $925 ($5 penalty) of the EVPI per patient. ConClusions: 
When decision-maker’s criteria go beyond costs and effects, standard VOI results 
may not reflect the actual value of additional research accurately and may there-
fore jeopardize optimal research prioritization. Determination of the extended 
VOI, through separation of cost, effect, and constraint components, is straightfor-
ward and can support optimal research prioritization regardless of the complexity 
of the decision criteria considered.
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objeCtives: Meta-analysis combines results from independent studies to pro-
duce robust statistical estimates. This technique is widely used in health care 
to synthesise treatment effects from clinical studies. However, when dealing 
with rare events such as rare adverse events, existing meta-analysis methods 
might not produce good treatment effect estimates, especially when there is no 
event occurrence in one or both arms of a study. The objective of this study is to 
compare the performance of various methods in estimating effect size for rare 
events. MetHoDs: An assessment of meta-analysis methods providing pooled 
odds-ratios as effect size estimates was conducted for different scenarios. The 
Inverse Variance Weighted, Peto, Mantel-Haenszel and logistic methods were 
assessed, with constant, “treatment arm” or empirical continuity corrections 
added when needed. The scenarios were created using different values of odds-
ratio, baseline risk, and group imbalance. For each scenario 5,000 simulations of 
10 studies were generated using R software. Coverage, bias and statistical power 
were used to compare the methods. Results: The most commonly used conti-
nuity correction is outperformed in every scenario by the two other corrections. 
The inverse variance method, most commonly used in meta-analysis, performs 
poorly when the event probability is smaller than 0.10: it is not recommended for 
sparse data. Peto’s method performs well in some scenarios but leads to biased 
results with high odds ratios and high imbalance. The logistic method is highly 
biased when baseline risk is low and true odds ratio is high. Under other scenarios 
it performs well but is most often outperformed by other methods. The Mantel-
Haenszel method with empirical correction performs constantly well over the 
scenarios. ConClusions: These findings may be used to develop guidelines on 
when to use which method for conducting meta-analysis with rare events. Next 
steps will be to assess the use of mixed models and Bayesian techniques.
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objeCtives: Propensity score matching (PSM) is an approach commonly used 
when treatment and control groups are thought to be different on key study vari-
ables. When the control group is larger than the treatment group, (as large as 20:1) 
a good match might be easy to obtain. However, differences may exist between the 
matched controls and the unmatched controls, indicating poor generalizability 
of study results. MetHoDs: Groups for the analysis are the unmatched controls 
(UM), the matched controls (MC) and the treatment cohort (TRT). Analysis methods 
for these groups in a fully crossed method and interpretation of the results will 
determine internal (IV) and external validity (EV). Analysis comparing the groups 
against the outcomes variable will determine if variables need to be controlled 
for in models that may be developed. Results: After the PSM is conducted MC 
and TRT groups should be compared on the matched variables. Differences at this 
stage would indicate a poor match and a low level of IV. MC and UM should also 
be compared on the variables used for matching, as well as the outcome variables 
of interest. Significant differences on the matched variables would indicate low 
EV and poor generalizability of results, while differences of MC and UM groups 
and UM and TRT groups on the outcome variables would indicate that statisti-
cal models would need to address covariates as potential confounding effects 
would be present. Analysis methods can be fit statistics (chi-square or equiva-
lence tests) or typical inferential methods with adjusted p-values greater than 
0.05. ConClusions: It is important that research studies maintain good IV and 
EV. This is often complicated in research where the controls vastly outnumber the 
treatment group. Proper statistical analysis can go a long way to test and clarify 
data to make the results as meaningful as possible.
(IPD) is available. In many situations, especially when Indirect Comparison (IC) 
methods are required to estimate head-to-head effects, it is often the case that 
IPD is only available for one trial, and summary data for the other. A variety of 
potential methods are evaluated for the adjustment of such summary data using 
simulation methodology. MetHoDs: A review of HTA submissions to NICE in 
which both ICs were used and in which trials were subject to treatment switch-
ing was undertaken. A series of simulation studies were undertaken to assess the 
potential level of bias associated with the methods that are most commonly used 
for the analysis of such trials. Two broad approaches to adjusting summary data 
for treatment switching were then evaluated on the simulated data – calculation of 
Adjustment Factors (AFs), and re-creation and analysis (including bootstrapping) 
of IPD using scanned survival curves. Results: The most commonly reported 
methods of analysis for studies only presenting summary data were Intention-
to-Treat (ITT) and Per Protocol (PP) analyses. Results from the simulation stud-
ies indicated that these may be subject to between 0.5% and 140% levels of bias 
depending on trial characteristics, and that the use of AFs or re-created IPD had 
potential scope for reducing this. ConClusions: Treatment switching can be 
associated with considerable levels of bias, and methods for adjusting using sum-
mary data, can go some way to compensating for this when IPD is not available 
as is often the case in Indirect Comparisons (IC). Further extension to a Network 
Meta-Analysis (NMA) setting is under investigation.
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objeCtives: Large scale survey data presents a number of challenges to imputa-
tion, not least the high number of variables and complexity of the data set. Data 
may suffer from sparsity in responses, and some questions may be conditional 
upon previous responses. In addition, survey data commonly contain results from 
multiple rating scales, which are summed (either directly or weighted) during 
analysis. We aim to develop a method for the multiple imputation of missing 
data from complex surveys. MetHoDs: We propose an adaptation of multiple 
imputation for survey data which contains multiple rating scales, whereby scale 
summary scores are used within the prediction models. The method is applied to 
data gathered from a large multinational survey, with data sets from 9 countries. 
Analysis uses a logistic regression model on each of the 9 data sets, and results 
are compared from a complete case analysis approach with those from multiple 
imputation. Results: The proposed approach reduces the size of the prediction 
models from 135 predictors to a maximum of 72. Distributions of imputed data are 
seen to be consistent with observed data. Results from the regression analysis with 
multiple imputation are similar to, but show lower standard errors than, results 
for complete case analysis; for the same regression models a 39% reduction in 
the standard error is observed. ConClusions: Our adaptation makes multiple 
imputation practical for large scale survey data with multiple rating scales. For 
the data considered, analysis of the multiply imputed data shows greater power 
and efficiency than complete case analysis. The adaptation of multiple imputation 
makes better use of available data and can yield substantively different results 
from simpler, less valid techniques.
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objeCtives: Subsequent therapies can confound the evaluation of overall survival 
(OS) in oncology trials. We evaluated the application of rank-preserving structural 
failure time modeling for the estimation of OS effects in presence of subsequent 
therapies through Monte Carlo simulations. Results were demonstrated for a clini-
cal trial: the Lux Lung 1 study of afatinib vs. placebo in non-small cell lung can-
cer. MetHoDs: In accelerated failure time models, covariates are assumed to affect 
survival times rather than hazard rates. Counterfactual survival times can therefore 
be computed, i.e. how long patients would have survived without the investigational 
or subsequent therapies. The parameters of structural failure time models can be 
obtained by G-estimation, whereby counterfactual survival times are calculated 
with hypothetical treatment effects and OS is compared between treatment arms. 
The G-estimate is the set of hypothetical effects that generate the most similar 
survival in both study arms. Branson & Whitehead (2002) developed an alternative 
estimation method for trials with cross-in from placebo to active treatment based 
on iterative parametric regressions; we extend this framework to the application 
with subsequent therapies. Results: Simulation showed that standard methods 
are biased in the presence of subsequent therapies affecting overall survival. This 
includes intent-to-treat analysis, censoring at start of subsequent therapies and 
subgroup analysis in patients never receiving subsequent therapy. G-estimation 
often failed to identify parameter values when more than one treatment effect was 
included in the model. Iterative parameter estimation produced unbiased estimates 
in simulation studies and predicted a small numeric but non-significant survival 
benefit of afatinib. ConClusions: Structural failure time models can be useful to 
obtain unbiased estimates of OS in presence of subsequent therapies. However the 
assumption of proportionality in survival times cannot be tested empirically and 
non-standard estimation procedures are required.
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